Article thumbnail

Antiviral effects of the combination of different treatments on influenza replication.

By Isabelle Marois (647579), Alexandre Cloutier (647580), Isabelle Meunier (401831), Hana M. Weingartl (169140), André M. Cantin (414230) and Martin V. Richter (647581)


<p>MDCK cells were treated as described in <a href="" target="_blank">Figure 1</a>. The combinations of calcium modulators with lysosomotropic alkalinizing agents was tested against the PR8 virus. Combination of a calcium modulator with a lysosomotropic alkalinizing agents (A, B, C, D), combination of two lysosomotropic alkalinizing agents (E), and combination of amodiaquine and oseltamivir carboxylate (F). Viral plaques were counted and results are expressed as a percentage of plaque formation compared to untreated cells (Plaque formation (%)). Statistical significance: p<0.05, **p<0.01, ***p<0.001. Results of three to six independent experiments, performed in triplicate are shown. Abbreviations used: Amodiaquine (Amo); 5-(N,N-Dimethyl)amiloride hydrochloride (5-N,N); Oseltamivir (Oselt); Primaquine (Prima); TMB-8 hydrochloride (TMB-8); Verapamil (Vera).</p

Topics: Biological Sciences, pa, lysosomotropic alkalinizing agents, influenza virus replication cycle, MDCK cells, Influenza Virus Replication, influenza virus infections target components, replication cycle, drugs classes, cm, Targeting Broad Host Cell Pathways Antivirals, influenza replication, laa, 8 h, drug development, acidic polymerase, calcium modulators
Year: 2014
DOI identifier: 10.1371/journal.pone.0110631.g003
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.